Peptonic Medical AB’s (publ) Annual Report 2016 published
Stockholm 7th March, 2017. - Peptonic Medical (publ) - a company developing pharmaceuticals based on oxytocin - today announced that the 2016 Annual Report is available on the company’s website www.peptonicmedical.se and on the AktieTorget website www.aktietorget.se .
For more information, please contact;
Johan Inborr, CEO
Telephone: +46 708 853 893
This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 7th March 2017.
Oxytocin is a peptide hormone that is produced within the neurons of the brain and released in to the blood stream. It is well known for its key role in labour and breast feeding, stimulating the contraction of the uterus and promoting milk ejection. Oxytocin has been used clinically since the 1960s as an IV drip and is also administered as an injection after childbirth to reduce uterine bleeding. More recently, oxytocin has been found to possess additional medicinal benefits as an anti-inflammatory agent, in promoting the healing of tissues as well as the possible reduction in certain types of pain.
Oxytocin is the active substance of Vagitocin®, which is currently being investigated for the treatment of vaginal atrophy in menopausal women. In this application, the oxytocin gel is administered vaginally.
About Peptonic Medical AB
Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products including for the treatment of menopausal symptoms, such as vaginal atrophy. Peptonic Medical’s mission is to develop safe and effective drugs based on the well-known beneficial properties of oxytocin.